Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2021

Tobalina L, Armenia J, Irving E, O'Connor M J, Forment J V

Abstract excerpt

BACKGROUND: Germline mutations in the BRCA1 or BRCA2 (BRCA) genes predispose to hereditary breast and ovarian cancer and, mostly in the case of BRCA2, are also prevalent in cases of pancreatic and prostate malignancies. Tumours from these patients tend to lose both copies of the wild-type BRCA gene, which makes them exquisitely sensitive to platinum drugs and poly(ADP-ribose) polymerase inhibitors (PARPi),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA End-Joining Repair

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 33091561
DOI: 10.1016/j.annonc.2020.10.470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.PMID 33091561Read ↗

A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity Read ↗

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.Semantic proximity Read ↗

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read ↗

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.Semantic proximity Read ↗

BRCA1/2 reversion mutations in a pan-cancer cohort.Semantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read ↗

Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer PatientsSemantic proximity Read ↗

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistanceSemantic proximity Read ↗

Landscape of reversion alterations in homologous recombination genes reveals evolutionary constraintsSemantic proximity Read ↗

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.Semantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.